Compare Cassava Sciences Inc (FLNA) vs Workday Inc (WDAY) Price & Performance

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

WDAY trades at $145.46, up 4.04% in the last session, with a bullish technical signal from moving averages and a consensus analyst price target of $157.30. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $2.62. Revenue growth remains robust, projected to reach $9.9 billion in 2026, while net income margin improved to 8.6% in 2025. Recent news highlights AI-driven expansion deals and partnership growth, though the stock faces a lawsuit over AI bias concerns.

WDAY presents a favorable risk-reward profile with strong fundamentals and analyst support, but investors must weigh competitive pressures and regulatory risks. The stock's current valuation at 44.18x P/E reflects growth expectations, yet persistent net cash outflows and high debt levels warrant caution. Upside potential hinges on execution of AI initiatives and sustained subscription revenue growth amid a volatile tech sector.